åŸææ®µéã®è£œè¬äŒç€Ÿã§ãã MEI Pharma, Inc. ã¯ãããæ²»çã®ããã®ããŸããŸãªæ²»çæ³ã®éçºãšåååã«éç¹ã眮ããŠããŸããå瀟ã¯ãåçºæ§/飿²»æ§æ¿Ÿèæ§ãªã³ãè
«ã®æ£è
ã®æ²»çã®ããã®ç¬¬ III çžèšåºè©Šéšãããã³ B çŽ°èæªæ§è
«çã®æ²»çã®ããã®ç¬¬ Ib çžå€çŸ€è©Šéšãè¡ãããŠããçµå£ãã¹ãã¡ããžã«ã€ãã·ããŒã« 3-ãããŒãŒ ãã«ã¿é»å®³å€ã® Zandelisib ãšãæ¥æ§éªšé«æ§çœè¡ç
ããã³ B çŽ°èæªæ§è
«çã®ããã®ç¬¬ Ib çžèšåºè©Šéšãè¡ãããŠããçµå£ãµã€ã¯ãªã³äŸåæ§ãããŒãŒ 9 é»å®³å€ã® Voruciclib ãéçºããŠããŸããå瀟ã¯ãŸããé
žåãªã³é
žåè€åäœãæšçãšããããã³ã³ããªã¢é»å®³å€ ME-344 ãéçºããŠãããããã¯ããäžç®æé·å ååå®¹äœ 2 é°æ§ä¹³ããã®æ²»çã®ããã®ç¬¬ I çžèšåºè©Šéšäžã§ãããŸããçµå£æäžå¯èœãªãã¹ãã³è±ã¢ã»ãã«åé
µçŽ é»å®³å€ã§ãããã©ã·ãã¹ã¿ããã¯ã骚é«ç°åœ¢æçåçŸ€ã®æ£è
ãæ²»çããããã®ç¬¬ II çžèšåºè©Šéšäžã§ããMEI Pharma, Inc. ã¯ãååããªã³æ ªåŒäŒç€Ÿãšã©ã€ã»ã³ã¹ãéçºãããã³åååå¥çŽãç· çµããŠããŸããBeiGene, Ltd. ãšã¯èšåºååé¢ä¿ã«ãããHelsinn Healthcare SA ãšã¯ã©ã€ã»ã³ã¹ãéçºã補é ãããã³åååå¥çŽãç· çµããŠããŸãããŸããPresage Biosciences, Inc. ãšã¯ã©ã€ã»ã³ã¹å¥çŽãç· çµããŠããŸããå瀟ã¯ä»¥å㯠Marshall Edwards, Inc. ãšããŠç¥ãããŠããŸãããã2012 幎 7 æã« MEI Pharma, Inc. ã«ç€Ÿåã倿ŽããŸãããMEI Pharma, Inc. 㯠2000 幎ã«èšç«ãããã«ãªãã©ã«ãã¢å·ãµã³ãã£ãšãŽã«æ¬ç€Ÿã眮ããŠããŸãã